Revolo Phase I site
Los Angeles, California, 90630, United States
NCT Number: NCT05921591
The purpose of this clinical study is to assess the safety, tolerability and pharmacokinetics of repeat doses of IRL201104 given to healthy volunteers.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Los Angeles, California, 90630, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
Lyophilised powder for reconstitution for IV dosing
Matching placebo for IRL201104
Time frame: 28 days
Number of subjects experiencing TEAE and number of TEAE will be summarised by treatment
Time frame: 28 days
Individual plasma levels will be listed and summarized by treatment and collection timepoint.
Time frame: 28 days
The presence of ADAs to IRL201104 will be listed and summarized by treatment group and timepoint.
Revolo Biotherapeutics
Industry
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of IRL201104 in Healthy Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07502417
Healthy Volunteer
Grayslake, Illinois, United States
View Trial DetailsNCT01934660
Cardiovascular Disease, Cardiovascular Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT06717269
Healthy Volunteer
Lincoln, Nebraska, United States
View Trial DetailsNCT00001367
Healthy Volunteer, Nervous System Disease
Bethesda, Maryland, United States
View Trial Details